Effects of Dihydropyridine Calcium Channel Inhibitors on Respiratory Gas Exchanges in the Intensive Care Unit: a Pharmacovigilance Study in VigiBase® and a Comparison With Urapidil
NCT ID: NCT05537194
Last Updated: 2022-09-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
32000000 participants
OBSERVATIONAL
1963-01-01
2022-08-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Relevance of Nicardipine Induced Hypoxemia in the Intensive Care Unit
NCT05155202
Enteral Nutrition and Vasoactive Drugs
NCT03401632
The Influence of Beta Blocker Therapy on the Hemodynamic Response to Inotrope Infusion in Patients With Acute Decompensated Heart Failure
NCT01971944
Effect of Nebulized Bronchodilators on Heart Rate
NCT01151579
Clevidipine in the Postoperative Treatment of Hypertension (ECLIPSE-NIC)
NCT00093925
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with hypoxia
dihydropyridine calcium channel inhibitors use
administration of dihydropyridine calcium channel inhibitors
Patients without hypoxia
dihydropyridine calcium channel inhibitors use
administration of dihydropyridine calcium channel inhibitors
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
dihydropyridine calcium channel inhibitors use
administration of dihydropyridine calcium channel inhibitors
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Caen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Caen University Hospital, Department of Pharmacology
Caen, Normandy, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pharmaco 20220908
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.